Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/2240
Title: | Characteristics of Children ≤36 Months of Age with Diffuse Intrinsic Pontine Glioma (DIPG): A Report from the International DIPG Registry | Authors: | Warren, K. Minturn, J. Bartels, U. Hansford, J. Ziegler, D. Diez, B. Goldman, S. Packer, R. Kieran, M. DeWire-Schottmiller, M. Erker, C. Monje-Deisseroth, M. Wagner, L. Koschmann, C. Dorris, K. Shih, C. S. Hassall, T. Samson, Y. Fisher, P. Wang, S. S. Tsui, K. Sevlever, G. Zhu, X. Dexheimer, P. Asher, A. Fuller, C. Drissi, R. Jones, B. Leach, J. Fouladi, M. Bartlett, A. Lane, A. Chaney, B. Escorza, N. Y. Black, K. Cochrane, A. |
Issue Date: | 2022 | Source: | , 2022 | Journal: | Neuro-oncology | Abstract: | BACKGROUND: Children ≤36 months with Diffuse Intrinsic Pontine Glioma (DIPG) have increased long-term survival (LTS, overall survival (OS) ≥24 months). Understanding distinguishing characteristics in this population is critical to improving outcomes. METHODS: Patients ≤36 months at diagnosis enrolled on the International DIPG Registry (IDIPGR) with central imaging confirmation were included. Presentation, clinical course, imaging, pathology and molecular findings were analyzed. RESULTS: Among 1183 patients in IDIPGR, 40 were eligible (median age: 29 months). Median OS was 15 months. Twelve patients (30%) were LTS, 3 (7.5%) very long-term survivors ≥ 5 years. Among 8 untreated patients, median OS was 2 months. Patients enrolled in the registry but excluded from our study by central radiology review or tissue diagnosis had median OS of 7 months. All but 1 LTS received radiation. Among 32 treated patients, 1-, 2-, 3-, and 5-year OS rates were 68.8%, 31.2%, 15.6% and 12.5%, respectively. LTS had longer duration of presenting symptoms (p=0.018). No imaging features were predictive of outcome. Tissue and genomic data were available in 18 (45%) and 10 patients, respectively. Among 9 with known H3K27M status, 6 had a mutation. CONCLUSIONS: Children ≤36 months demonstrated significantly more LTS, with an improved median OS of 15 months; 92% of LTS received radiation. Median OS in untreated children was 2 months, compared to 17 months for treated children. LTS had longer duration of symptoms. Excluded patients demonstrated a lower OS, contradicting the hypothesis that children ≤36 months with DIPG show improved outcomes due to misdiagnosis.L6379887722022-05-19 | DOI: | 10.1093/neuonc/noac123 | Resources: | https://www.embase.com/search/results?subaction=viewrecord&id=L637988772&from=exporthttp://dx.doi.org/10.1093/neuonc/noac123 | | Keywords: | survivor;outcome assessment;male;major clinical study;human;preschool child;radiology;female;pontine glioma;articlecancer patient;cancer survival;child;controlled study;diagnostic error | Type: | Article |
Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.